Category: Wall Street Beat
St. Jude Medical agrees to settle product liability lawsuits filed over its recalled Riata defibrillator leads and a class-action shareholder's suit accusing it of inflating results for its 2009 3rd quarter.
Bellerophon Therapeutics shares are down nearly 21% since their $12-per-share debut earlier this month.
Bellerophon Therapeutics (NSDQ:BLPH) shares are down nearly 21% since its IPO 2 weeks ago, when the stock in the New Jersey-based drug-device company opened at $10 per share, down 16.7% right out of the gate.
Here's a look at some of the top Wall Street stories for medical device companies this week: ViewRay registers for $69m IPO; Bellerophon prices $60m IPO low, issues more shares; Cutera expands stock buyback to $40M
Cutera's board of directors has expanded the company's stock buyback plan from $10 million to $40 million, the company announced Wednesday.
Cutera's (NSDQ:CUTR) board of directors has expanded the company's stock buyback plan from $10 million to $40 million, the company announced Wednesday.
ViewRay registers for an initial public offering worth up to $69 million for its MRIdian cancer detection and radiation treatment device.
ViewRay last week said it plans to raise up to $69 million in an initial public offering for its MRIdian system, which it bills as "the 1st and only MRI-guided radiation therapy system that images and treats cancer patients simultaneously."
Bellerophon Therapeutics prices its initial public offering under range, but issues a million more shares than planned, for a gross take of $60 million.
Zimmer revises its $13 billion bid for crosstown rival Biomet in a further effort to mollify European anti-trust regulators, saying it thinks the deal is still on track to close during the 1st quarter.